CureVac N.V. (NASDAQ:CVAC) Given Consensus Recommendation of “Hold” by Analysts

CureVac N.V. (NASDAQ:CVAC) has earned a consensus rating of “Hold” from the six ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $6.8333.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CureVac in a research report on Tuesday, December 16th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of CureVac during the first quarter valued at approximately $142,000. Integrated Wealth Concepts LLC grew its position in CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after purchasing an additional 3,000 shares in the last quarter. Millennium Management LLC raised its stake in CureVac by 10.3% during the 1st quarter. Millennium Management LLC now owns 1,816,984 shares of the company’s stock valued at $5,033,000 after purchasing an additional 169,947 shares during the period. Plato Investment Management Ltd purchased a new stake in shares of CureVac in the first quarter valued at $84,000. Finally, Baron Wealth Management LLC purchased a new stake in shares of CureVac in the second quarter valued at $107,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Trading Down 0.2%

Shares of NASDAQ:CVAC opened at $4.66 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of 6.47 and a beta of 1.77. CureVac has a 1-year low of $4.00 and a 1-year high of $4.68. The company has a 50 day moving average price of $4.93 and a 200 day moving average price of $5.24.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Monday, November 24th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $63.53 million during the quarter, compared to the consensus estimate of $21.40 million. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%. On average, research analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.

CureVac Company Profile

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.